biologics

Back on January 11, 2017, before he was even inaugurated, then-President-elect Donald Trump laid out his ambitions for the US pharma industry. He called for reversing the trend of the past decade – which was to outsource manufacturing overseas -- and a return to domestic production. Trump was right of course, but Congress, more intent on destroying his presidency than helping America, failed to act on legislation that might have helped and the industry has remained focused on reducing costs.